- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT07426250
Utilità Clinica del ctDNA nel Trattamento della Malattia Oligometastatica
Utilità Clinica del ctDNA nel Trattamento della Malattia Oligometastatica - Uno Studio Clinico Osservazionale Prospettico - Parte del Progetto POB
This prospective observational study investigates the clinical utility of circulating tumor DNA (ctDNA) in patients with oligometastatic disease (OMD) undergoing definitive-intent local ablative treatment (LAT). The study aims to evaluate ctDNA as a prognostic and response biomarker before, during, and after LAT across cancer types and treatment modalities. Serial plasma samples and archival tumor tissue will be analyzed to assess ctDNA detection rates, elimination patterns, minimal residual disease, and association with recurrence, progression, and survival outcomes.
Panoramica dello studio
Stato
Condizioni
Descrizione dettagliata
Oligometastatic disease (OMD) represents an intermediate disease state between localized and polymetastatic cancer and may be amenable to curative or long-term disease-controlling local ablative treatment (LAT). Despite careful patient selection, recurrence rates after LAT remain substantial, highlighting the need for improved biological markers to guide treatment decisions and follow-up.
Circulating tumor DNA (ctDNA) is a promising biomarker for prognostication, response assessment, and early detection of recurrence. Pilot studies and systematic reviews conducted by the study group indicate that ctDNA dynamics before and after LAT are associated with treatment outcomes. However, important knowledge gaps remain regarding ctDNA detection rates, elimination patterns, optimal sampling time points, and clinical relevance across metastatic sites, treatment modalities, and oligometastatic states.
This prospective observational study, conducted as part of the Pan-Cancer Oligometastatic Biology (POB) project, will enroll patients with oligometastatic solid tumors planned for definitive-intent LAT. Serial blood samples will be collected before treatment, during treatment when applicable, and throughout follow-up. ctDNA and total circulating free DNA will be analyzed using sensitive molecular techniques. Archival tumor tissue will be retrieved for tumor-informed analyses.
The study will evaluate ctDNA detection rates, elimination patterns, minimal residual disease, lead time to radiological recurrence, and associations with disease-free survival, progression-free survival, and overall survival. Exploratory analyses of immune-related biomarkers will also be performed. The results are expected to support improved biological stratification and monitoring strategies in oligometastatic disease.
Tipo di studio
Iscrizione (Stimato)
Contatti e Sedi
Contatto studio
- Nome: Louise B Callesen, MD, PhD
- Numero di telefono: 30482884
- Email: Louicall@rm.dk
Backup dei contatti dello studio
- Nome: Karen-Lise G Spindler, Professor, MD, PhD
- Numero di telefono: 91167244
- Email: K.g.spindler@oncology.au.dk
Luoghi di studio
-
-
-
Aarhus N, Danimarca, 8200
- Reclutamento
- Department of Oncology, Aarhus University Hospital
-
Contatto:
- Louise B Callesen, MD, PhD
- Numero di telefono: 30482884
- Email: Louicall@rm.dk
-
Investigatore principale:
- Louise B Callesen, MD, PhD
-
Investigatore principale:
- Karen-Lise G Spindler, Professor, MD, PhD
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Metodo di campionamento
Popolazione di studio
The study population consists of patients with verified oligometastatic cancer disease who are planned for local ablative therapy.
Descrizione
Inclusion Criteria:
- Metastatic spread from histopathological diagnosed solid cancer
- Planned for LAT (local ablative therapy) for OMD (oligometastatic disease)
- ≥ 18 years
- Written and oral consent
Exclusion Criteria:
- Other cancer disease within 5 years
- Conditions that will contraindicate blood samples
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Modelli osservazionali: COHORT
- Prospettive temporali: PROSPECTIVE
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Association between longitudinal ctDNA status and clinical outcomes after local ablative treatment
Lasso di tempo: During follow-up up to 5 years
|
Presence and dynamics of circulating tumor DNA (ctDNA) assessed before LAT, after LAT, and during follow-up, and their association with clinically relevant outcomes including radiologically confirmed recurrence or progression, survival status, and lead time to recurrence. |
During follow-up up to 5 years
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Detection rate of ctDNA prior to local ablative treatment
Lasso di tempo: Baseline (pre-LAT)
|
The proportion of patients with detectable circulating tumor DNA in plasma prior to initiation of local ablative treatment will be assessed. Detection rates will be evaluated overall and stratified by treatment modality, cancer type and metastatic site |
Baseline (pre-LAT)
|
|
Elimination patterns of ctDNA following local ablative treatment
Lasso di tempo: During follow-up up to 5 years
|
Changes in ctDNA levels following local ablative treatment will be analyzed to characterize elimination patterns over time. Changes in ctDNA will be assessed in relation to treatment modality, cancer type, metastatic site, and timing of sampling to evaluate biological response to treatment |
During follow-up up to 5 years
|
|
Correlation between ctDNA and pathological response
Lasso di tempo: During follow-up up to 5 years
|
ctDNA status and ctDNA changes will be correlated with pathological response |
During follow-up up to 5 years
|
|
Correlation between ctDNA and risk of recurrence or early progression
Lasso di tempo: Up to 5 years
|
The association between ctDNA and the subsequent risk of recurrence or early disease progression will be evaluated |
Up to 5 years
|
|
Correlation between ctDNA and disease-free survival or progression-free survival
Lasso di tempo: Up to 5 years
|
Disease-free survival or progression-free survival will be analyzed according to ctDNA status at baseline, post-treatment, and during follow-up to assess the prognostic value of ctDNA in patients treated with definitive-intent local ablative treatment |
Up to 5 years
|
|
Correlation between ctDNA and overall survival
Lasso di tempo: Up to 5 years
|
Overall survival will be analyzed according to ctDNA status at baseline, post-treatment, and during follow-up to assess the prognostic value of ctDNA in patients treated with definitive-intent local ablative treatment |
Up to 5 years
|
|
Rate of ctDNA-detected minimal residual disease
Lasso di tempo: up to 5 years
|
The proportion of patients with detectable ctDNA following completion of definitive-intent local ablative treatment, consistent with molecular minimal residual disease, will be determined and analyzed in relation to clinical outcomes |
up to 5 years
|
|
Lead time between ctDNA detection and imaging-confirmed recurrence or progression
Lasso di tempo: During follow-up up to 5 years
|
The time interval between first detection of ctDNA during follow-up and subsequent radiological confirmation of recurrence or progression will be calculated to estimate the potential lead time provided by ctDNA monitoring |
During follow-up up to 5 years
|
|
Exploratory analysis of total circulating free DNA
Lasso di tempo: Up to 5 years
|
Total circulating free DNA levels will be quantified and analyzed exploratorily in relation to treatment, ctDNA status, imaging findings, and clinical outcomes to assess potential additional biological or prognostic value |
Up to 5 years
|
Collaboratori e investigatori
Sponsor
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Altri numeri di identificazione dello studio
- 1-10- 72-122-25
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .